Custom biomimetic-functionalized lipid nanoparticle (LNP) development covering membrane source selection, membrane coating and fusion engineering, bio-inspired surface design, interface characterization, and functional delivery evaluation.
Conventional LNPs are efficient carriers, but their synthetic surface is quickly recognized by the body: plasma proteins adsorb onto the particle, immune cells clear a large fraction from the blood, and most of the dose accumulates in the liver. Biomimetic functionalization addresses these problems by giving LNPs a surface that resembles a natural biological structure, such as a cell membrane, a lipoprotein particle, or an exosome. The result can be longer circulation, reduced nonspecific uptake, and source-cell-directed targeting.
A complete natural membrane offers many functions at once but is harder to control; a fully synthetic mimic is more reproducible but delivers fewer biological features. In between lie hybrid membranes, membrane-protein extracts, and protein-corona-programmed surfaces. The right choice depends on the payload, the target tissue, and how much biological complexity a project can tolerate.
BOC Sciences provides integrated targeted LNP development that connects biomimetic surface engineering with proven LNP core formulation. We support mRNA, siRNA, gene-editing cargo, proteins, small molecules, and imaging payloads, and we deliver decisions based on measurable formulation and functional data rather than assumptions.
Schematic of Biomimetic Surface-Modified LNPsOur services cover the full chain of biomimetic LNP development: selecting and preparing the biological material, building and loading the LNP core, fusing the biomimetic surface onto the particle, and verifying that the construct works in biologically relevant models. Each work package can be used alone or combined into a comparative development program.
We help you choose the biological source that matches your delivery objective, then prepare membrane vesicles or derived components under conditions that preserve surface proteins.
The LNP core is engineered together with the biomimetic surface so that payload performance survives surface modification.
Coating quality decides whether the biomimetic functions are actually displayed on the particle. We optimize the fusion process instead of applying one fixed protocol.
Beyond natural coating, we tailor the biomimetic interface with additional functional elements.
We characterize both the particle and the biological interface, because size data alone cannot confirm a successful coating.
We test whether the biomimetic surface changes biological behavior in the way the design intends.
Biomimetic functionalization introduces biological recognition, transport, or membrane-interaction functions that conventional LNPs may lack. Cell membranes, extracellular vesicle components, apolipoproteins, viral-inspired elements, or pathogen-associated structures can be integrated with LNPs to improve circulation, tissue interaction, cellular uptake, membrane fusion, or intracellular payload release.
Cell membranes are coated or fused onto LNPs to transfer source-cell surface proteins, lipids, and glycans that support circulation, adhesion, or cell-specific interactions.
Virus-inspired LNPs reproduce selected viral mechanisms for membrane fusion or intracellular entry, helping address cellular uptake and endosomal escape.
Lipoprotein-mimicking LNPs use apolipoproteins and lipid compositions that engage endogenous lipid-transport pathways and receptor-mediated uptake.
Exosome-mimicking LNPs combine selected extracellular-vesicle features with a controllable synthetic lipid core to support biological recognition and payload delivery.
Hybrid membrane LNPs combine two biological membrane sources to integrate complementary functions such as prolonged circulation and targeted tissue interaction.
Pathogen-associated membrane components can be integrated with LNPs to promote recognition by immune cells or reproduce selected microbial surface interactions.
Share your payload, target tissue, and biological model. We can compare feasible biomimetic routes and define the characterization package needed to choose one with confidence.
Biomimetic membranes can be introduced onto LNPs by mechanical coating, membrane fusion, controlled mixing, or hybrid assembly. Method selection depends on membrane source, LNP composition, payload sensitivity, membrane-protein stability, and whether the goal is a complete outer coating or a mixed biological-synthetic membrane. The preparation method can directly affect particle size, coating completeness, membrane-protein retention, and surface orientation.
Membrane vesicles and preformed LNPs are repeatedly passed through a porous membrane under controlled pressure. Mechanical deformation brings the two lipid structures into close contact and promotes formation of a membrane-coated or hybrid particle.
Membrane vesicles are mixed with LNPs and exposed to controlled ultrasonic energy. Temporary disruption and reorganization of the lipid bilayers promotes contact and fusion between the biological membrane and synthetic lipid surface.
Biological membrane components, synthetic lipids, and selected payloads are combined through controlled microfluidic mixing. Rapid and reproducible fluid contact can support simultaneous nanoparticle formation and incorporation of membrane-derived components.
Short electrical pulses can transiently destabilize lipid membranes, increasing membrane permeability and promoting interaction between biological vesicles and lipid-based carriers. For biomimetic LNP development, electroporation is generally considered an auxiliary membrane-engineering method rather than the default coating route.
Preformed membrane vesicles and LNPs are brought together under conditions that favor lipid exchange and bilayer fusion. Fusion may be assisted by incubation, freeze-thaw cycling, fusogenic lipids, or other mild membrane-reorganization conditions.
Membranes from two or more biological sources are first combined to create a hybrid membrane and then fused with or coated onto the LNP. The source ratio can be adjusted to balance complementary functions such as circulation, vascular adhesion, inflammatory homing, or homotypic recognition.
Different membrane sources, payloads, and LNP compositions require different coating or fusion conditions. Share your membrane source and formulation requirements, and BOC Sciences can help compare suitable assembly routes and optimize coating integrity, membrane-protein retention, and particle performance.
Biomimetic functionalization gives LNPs a biological interface that synthetic surfaces struggle to reproduce. The benefits below are design-dependent, which is why we treat each project as a comparative development task.
Native-Like Biological Surface Presentation
A biomimetic shell presents proteins, lipids, and glycans in their natural arrangement rather than as isolated conjugated ligands. This allows the particle to interact with cells and proteins the way a biological structure would, which is difficult to recreate with single-ligand chemistry.
Cell-Source-Derived Targeting and Adhesion
The choice of membrane source defines the behavior: tumor cell membranes support homotypic tumor binding, platelet membranes support adhesion at injured vasculature, and immune cell membranes support homing to inflamed tissue. Targeting can therefore be selected by source rather than engineered ligand by ligand.
Reduced Nonspecific Biological Recognition
Self-markers such as CD47 on natural membranes interact with macrophage checkpoints, and dense glycan layers reduce nonspecific protein adsorption. Compared with purely synthetic surfaces, this can reduce opsonization-driven clearance and support longer circulation in research models.
Combination of Biomimetic Surfaces with Tunable LNP Cores
The biomimetic shell does not lock the project into one payload or formulation. The core remains a fully engineerable LNP whose lipid composition, size, and loading can be optimized for the payload while the surface supplies the biological interface.
BOC Sciences develops biomimetic-functionalized LNPs for the payload classes most used in targeted delivery research. Each payload raises specific questions, such as whether membrane coating disturbs encapsulation, or whether the biomimetic surface changes uptake in the intended cell model. We address these with matched controls and functional readouts.
| Payload Type | Supported Uses & Biomimetic LNP Development Considerations | Request Information |
|---|---|---|
| mRNA and Reporter RNA | Suitable for expression studies, protein replacement research, and vaccine-oriented models where the biomimetic surface directs uptake into defined cell populations. Development balances encapsulation, membrane coating integrity, and expression readouts, building on our lipid nanoparticles for mRNA delivery platform. | Inquiry |
| siRNA and Gene-Silencing Cargo | Designed for knockdown studies in homotypic tumor models, inflammation research, and extrahepatic delivery programs. We track encapsulation, free-RNA removal, uptake selectivity, and knockdown relative to uncoated controls, supported by our lipid nanoparticles for siRNA delivery services. | Inquiry |
| pDNA and Gene-Editing Cargo | Applicable to plasmid delivery and gene-editing systems that require strong protection and efficient intracellular release. Work focuses on large-cargo loading, membrane-coating compatibility, and functional editing or expression readouts, drawing on lipid nanoparticles for gene delivery experience. | Inquiry |
| Protein and Peptide Payloads | Suitable for enzymes, binding proteins, antigens, and functional peptides studied in source-cell-targeted delivery models. Development emphasizes mild coating conditions, aggregation control, and retention of protein activity, supported by our protein encapsulation in LNPs capabilities. | Inquiry |
| Small Molecule Payloads | Designed for hydrophobic and amphiphilic compounds in long-circulating or tumor-targeted delivery research. We consider drug–lipid compatibility, leakage during membrane fusion, and release behavior, in line with our lipid nanoparticles for small molecule delivery services. | Inquiry |
| Antigen and Immunomodulatory Cargo | Supports antigen–adjuvant combinations and immune-modulating payloads delivered with pathogen-mimicking or immune-cell-derived surfaces for vaccine and immunology research. Related formulation work is anchored in lipid nanoparticles for antigen delivery. | Inquiry |
| Co-Delivery Systems | Applicable to systems combining a nucleic acid with a second payload class, where ratio control and uniform coating both matter. We evaluate co-encapsulation behavior, membrane compatibility, and paired functional readouts under matched conditions. | Inquiry |
| Fluorescent and Imaging Payloads | Supports labeled RNA, dyes, and tracking probes used to visualize biomimetic uptake, trafficking, and distribution. Labeling strategies can be combined with our fluorescent-labeled lipid nanoparticles services. | Inquiry |
Tell us your payload, target tissue, and delivery goal. BOC Sciences will propose a biomimetic surface strategy and a formulation plan that fits your project.
A biomimetic LNP can look correct under basic sizing yet fail biologically. Most failures trace back to the interface, where the biological surface meets the synthetic core. We diagnose these problems with comparative experiments instead of repeated trial and error.
Incomplete or Heterogeneous Membrane Coating
Particles with patchy shells show mixed behavior: some evade clearance, others do not. We compare coating methods and membrane input, then confirm shell continuity by electron microscopy and protein quantification before biological testing.
Loss of Membrane Proteins During Processing
Harsh lysis, sonication, and long processing times strip or denature the very proteins that provide biomimetic function. We use gentle extraction, protease protection, and shortened processing, then verify retention of the marker proteins relevant to your mechanism.
Incorrect Membrane Orientation and Poor Surface Accessibility
A fraction of coated membranes always sits inside-out, hiding functional proteins from the outside. We measure sidedness with enzymatic and antibody-accessibility assays and adjust fusion conditions to raise the correctly oriented fraction.
Aggregation and Instability After Membrane Functionalization
Membrane excess, charge mismatch, and serum exposure can drive particle association after coating. We screen membrane-to-core ratios and buffer conditions, and we run serum-challenge stability tests to identify formulations that hold their size and shell.
Weak Targeting or High Nonspecific Cellular Uptake
When biomimetic particles enter all cell types equally, the surface function is not engaged. We add matched control cells, blocking conditions, and source-mismatched membranes to determine whether uptake is genuinely source-directed.
Reduced Payload Delivery After Membrane Coating
A membrane shell can slow endosomal processing and trap cargo, so uptake gains do not become expression or silencing gains. We compare intracellular trafficking and functional readouts, with optional LNP endosomal escape evaluation, to locate the limiting step.
Tell us where the project is stuck: membrane preparation, coating quality, particle stability, or biological performance. BOC Sciences can design a focused troubleshooting study with matched controls and clear analytical endpoints.
Projects can start from an existing LNP, an isolated membrane source, or only a delivery objective. We organize the work into four stages and refine the plan as formulation and biological evidence accumulate.
We review the payload class, target tissue or cell model, route of laboratory exposure, and any existing formulation. The biomimetic route is chosen against these inputs: a natural membrane, a hybrid membrane, a vesicle hybrid, or a synthetic mimic, each with its own characterization needs.
The LNP core is formulated and loaded with the payload while the biological material is extracted and converted into membrane vesicles or defined biomimetic components. Both streams are quality-controlled: particle size and encapsulation on one side, vesicle size, purity, and protein profile on the other.
Core and membrane are combined via the selected fusion route, and variables such as membrane input, energy input, and incubation conditions are screened. As part of LNP process optimization, we purify the product and confirm coating completeness before any biological work begins.
Coated candidates are characterized for size, shell structure, protein retention, and stability, then evaluated in the agreed cell models with matched uncoated controls and blocking conditions. Functional endpoints, such as expression, silencing, or payload activity, are reported together with the formulation data so the next decision is evidence-based.
Biomimetic functionalization can extend LNP applications beyond conventional passive delivery by introducing biological recognition, adhesion, transport, or barrier-crossing functions. Depending on the application, cell membranes, lipoprotein-like surfaces, extracellular-vesicle components, or biomimetic peptides can be selected to improve interactions with specific tissues while the LNP core carries RNA, proteins, small molecules, or other functional payloads.
Cancer cell membranes, extracellular-vesicle-derived membranes, and engineered biomimetic surfaces can provide multiple tumor-associated interaction mechanisms that are difficult to reproduce with a single targeting ligand.
Biomimetic lipid nanoparticles can reproduce selected platelet adhesion and coagulation functions, making them useful components of local hemostatic and wound-repair systems.
Injured tissues often express receptors and surface markers that differ from healthy tissue. Biomimetic LNPs can exploit these changes to concentrate anti-inflammatory, antifibrotic, or regenerative payloads at damaged sites.
Biomimetic lipoprotein-like nanoparticles provide a strategy for improving protein transport across ocular barriers that normally restrict topical delivery to posterior eye tissues.
Biomimetic peptide-functionalized LNPs can be explored for immune-related research, gut microbiome modulation, diagnostic imaging and biosensing, tissue repair, and other emerging applications. Tell us your target, payload, and intended function, and BOC Sciences can help translate your concept into a practical LNP design, formulation, and evaluation strategy.
Challenge: An oncology research group needed homotypic delivery of siRNA against a proliferation-pathway target into a triple-negative breast cancer (TNBC) model. Their first cancer-cell-membrane-coated LNP was prepared by extended sonication: particle size rose from about 95 nm to roughly 180 nm, the PDI exceeded 0.35, and membrane-protein retention measured below 45%. Uptake in the homologous tumor cells was barely higher than the uncoated LNP, and knockdown could not be separated from nonspecific effects.
Diagnosis: BOC Sciences found that prolonged sonication was fragmenting membrane proteins and driving membrane excess onto each particle, producing multilamellar aggregates. The preparation also contained free membrane vesicles that were not removed before assays, inflating apparent uptake and blurring the readout.
Solution: We isolated membrane fractions from the matched TNBC cells, converted them into nanoscale membrane vesicles, and used these vesicles as the biomimetic surface layer for the siRNA-loaded LNP core. Three functionalization routes, extrusion, brief low-power sonication, and microfluidic-assisted fusion, were compared across four membrane-to-lipid ratios. After purification, candidates were assessed for membrane coverage, adhesion-protein retention, outward protein accessibility, particle properties, and homotypic uptake.
Result: Microfluidic-assisted fusion at an intermediate membrane input gave the best balance: an average size near 125 nm, PDI below 0.20, and retention of major adhesion proteins above 80%. Homologous tumor-cell uptake was about four-fold higher than the uncoated LNP and remained low in the mismatched cell line, and target knockdown reached about 65% in the homotypic model. The client advanced a lead candidate whose selectivity could be explained by characterized membrane composition instead of assumed targeting.
Challenge: A delivery team wanted siRNA activity outside the liver, focusing on inflamed pulmonary vasculature in a rodent research model. Their standard LNP delivered almost all of its siRNA to the liver, and their first platelet-membrane-coated version lost part of its shell during serum incubation, with visible aggregation and no benefit at the target site.
Diagnosis: BOC Sciences identified two coupled problems. The near-neutral core and the negatively charged platelet membrane interacted weakly, so the coating desorbed in serum; and the remaining PEG-lipid layer, designed for the uncoated particle, sat between the core and the membrane and further weakened shell adhesion.
Solution: We prepared platelet-derived membrane vesicles retaining key surface markers such as P-selectin and GPIb-associated proteins, then functionalized the siRNA-LNP core with this biomimetic membrane layer. The helper-lipid and cholesterol balance was adjusted to improve membrane integration, while PEG-lipid was reduced to limit surface masking. Extrusion and electroporation-assisted assembly were compared, followed by purification, serum-stability testing, platelet-marker accessibility analysis, and in vivo distribution and silencing evaluation.
Result: The optimized platelet-membrane LNP held its size shift below 10% after the serum challenge and retained its platelet-marker profile. In the rodent model, hepatic siRNA signal fell by roughly 2.5-fold compared with the uncoated LNP, siRNA signal at the inflamed lung vasculature was about three-fold higher, and target-gene knockdown at the lesion site reached approximately 55%. The client obtained both a working extrahepatic candidate and a set of serum-stability criteria for screening future coated formulations.
Biomimetic Design Integrated with LNP Payload EngineeringMembrane work and LNP formulation are handled in one coordinated plan, so surface modification does not come at the cost of encapsulation, stability, or payload function.
Source-Material Options Matched to Delivery ObjectivesWe work across red blood cell, platelet, immune cell, tumor cell, stem cell, and vesicle sources, and we recommend a source, or a hybrid, based on the delivery question rather than convenience.
Layered Characterization of the Biological InterfaceSize and zeta potential are only the beginning. We verify coating completeness, protein retention, membrane sidedness, and serum stability so that biological results can be interpreted at the interface level.
Mechanism-Informed Cellular and Distribution EvaluationMatched uncoated controls, source-mismatched membranes, and blocking conditions are built into our studies, distinguishing genuine biomimetic recognition from nonspecific nanoparticle uptake.
Reproducibility-Focused Process DevelopmentBecause biological source material introduces variability, we define extraction, coating, purification, and release criteria that keep independent batches comparable throughout a project.
Biomimetic-functionalized LNPs combine a tunable synthetic lipid core with biological components such as cell membranes, extracellular-vesicle membranes, apolipoproteins, viral-inspired fusion elements, or pathogen-associated structures. These additions can introduce functions that conventional LNPs may not provide efficiently, including prolonged circulation, vascular adhesion, homotypic recognition, receptor-associated uptake, membrane fusion, and improved intracellular release. They can be developed for siRNA, mRNA, proteins, peptides, small molecules, imaging agents, and gene-editing payloads. BOC Sciences selects the biomimetic strategy according to the specific delivery barrier that needs to be addressed rather than applying the same membrane coating to every formulation.
The membrane source should be selected according to the target tissue, desired biological interaction, payload, and delivery objective. Red blood cell membranes are often explored for circulation-related properties, platelet membranes for vascular and injury-associated interactions, leukocyte membranes for inflammatory homing, and cancer cell membranes for homotypic recognition. Extracellular-vesicle-derived membranes can provide a different set of adhesion and communication-related surface components. Hybrid membranes are also useful when one source does not provide all required functions. BOC Sciences can compare membrane sources and source combinations based on the target model, LNP core, payload properties, and planned functional readouts.
Biomimetic membranes can be integrated with LNPs through extrusion-based coating, controlled sonication, membrane-vesicle co-fusion, microfluidic-assisted assembly, or hybrid membrane preparation. In a typical workflow, the biological membrane is isolated, processed into nanoscale vesicles, and then fused with or coated onto a preformed payload-loaded LNP. Selected membrane proteins, apolipoproteins, or biomimetic peptides can also be introduced through lipid anchors or membrane insertion. Because each assembly route affects membrane integrity, protein orientation, particle size, and payload stability differently, BOC Sciences compares practical coating or fusion conditions rather than relying on a single universal preparation method.
Successful biomimetic functionalization requires more evidence than a change in particle size or zeta potential. Characterization should determine whether the biological membrane is truly associated with the LNP, whether free membrane vesicles have been removed, whether important membrane proteins remain intact, and whether their functional domains are accessible on the particle surface. Stability in relevant media and payload retention should also be examined. Functional validation may include matched and mismatched cell models, competition or blocking studies, uptake measurements, intracellular localization, and payload-specific endpoints. BOC Sciences combines these structural and biological readouts to distinguish genuine biomimetic activity from nonspecific nanoparticle uptake.
Yes. BOC Sciences can develop biomimetic LNPs for siRNA, mRNA and other RNA formats, proteins, peptides, small molecules, imaging agents, and multi-payload systems. A project may begin with an existing LNP formulation, an available biological membrane source, or only a target application concept. We can design the LNP core, membrane preparation, membrane-to-lipid ratio, coating or fusion strategy, and characterization plan around the payload and desired biological function. Projects can also explore emerging applications such as immune-disease research, gut microbiome modulation, diagnostic imaging, tissue repair, or other specialized delivery concepts, translating an early idea into a testable biomimetic LNP design.
